A study in which a group of HIV-negative gay and bisexual
men from New York were asked to predict each day whether they would have sex
the following day, and then compared their prediction with what actually
happened, found that men generally overestimated the likelihood they would have
sex.
The only time men accurately predicted whether they would
have sex the next day was in the days they predicted it was very unlikely: if
men reported that there was only a zero to 5% chance of sex the following day
then, sure enough, only about 4% actually ended up having sex and there was no
case in which someone had sex after having predicted that there was zero chance of them having sex the
following day. The sexual optimists, on the other hand, were often
disappointed: only 45% of men who predicted a 90% chance of sex the following day actually ended up having it.
The study
In this study, 92 gay men and other men who have sex with
men (MSM) from New York aged over 18 were asked to keep online sexual diaries
every day for 30 days. The mean
completion rate was 78%. The men were asked to say whether they had had sex
(where sex meant “anal intercourse with a casual partner”) and also rate the
likelihood, from zero to 100%, that they would also have anal sex with a casual
partner the following day.
This was a very mixed group of MSM. Their mean age was 33
but a quarter were under 22 and a quarter over 44; 54% were white, 14% black and
14% Latino; 16% defined as bisexual, rather than gay; roughly equal proportions
were in full-time work, part-time work and unemployed/student; and two-thirds
had been to university. Only one in six had a current steady relationship.
Fifty-nine per cent reported they had sex on three or more days per week.
Although there was a correlation between the prediction of
sex and its occurrence, the men were in general more likely to overestimate
rather than underestimate their chances of casual sex the following day. If men
said they thought there was a 100% chance of sex the following day, only 58%
actually had it: if a 50% chance, only 20% had it; if a 20% chance, only 10%
had it. Only if men rated their chances of sex as very low were their forecasts
accurate: for instance, where men rated their chances as 1-10%, about 5% had
sex, and if they thought there was no chance, they did not end up having sex.
Implications for PrEP regimens
The researchers comment that these findings have
implications for studies of intermittent PrEP: while so far intermittent-PrEP
studies have tended to instruct participants to take PrEP if they think they are likely to have sex the next day, it
might be safer, and in certain situations more cost-effective, they comment, to tell
participants: “take PrEP daily unless you are definitely not going to have sex
tomorrow; then you can miss a dose.”
This strategy would have to be quite strict, however.
Although participants generally overestimated their chances of having sex, when
the researchers ‘worked backwards,’ i.e. looked at occasions of sex and then
looked at whether participants had predicted it, they found a number of ‘false
negatives’: cases where people had ended up having sex even though they had
rated the probability as low.
This means that, if a
group of gay men similar to those in this study were told to take PrEP if they
thought they would have sex, there
was a substantial number of ‘false positives’, to the extent that only 20% of
PrEP doses taken would actually being needed. However 3.8% of occasions
of sex would be ‘false negatives’, i.e. not covered by PrEP. There were only no
‘false negatives’ if participants were absolutely
certain they would not have sex the following day.
Given that, while ‘false positives’ only waste money, but a
‘false negative’ may end up with an HIV infection, the researchers recommend
that the safest advice would be to advise PrEP takers that they can skip a dose
only there is “no chance” they will
have sex the following day.
While most studies of pre-exposure prophylaxis (PrEP) have
involved taking a daily dose of antiretroviral drugs to prevent HIV, some
studies have looked at, and are looking, at intermittent dosing of one sort or
another. Intermittent dosing may lower the possibility of side-effects, but the
main motive for investigating it is cost: with each Truvada (tenofovir/emtricitabine) pill in the US costing $25.86 (£17), the researchers estimate, it could save $4700 a year per person
(£3110) if people took PrEP only every other day, or only 50% of the time.
Recently the French IPERGAY study, which randomised gay men
to take two Truvada or placebo pills two to twelve
hours before they anticipated sex, and then to take two more in the two days
after sex if it actually happened, stopped
its randomised phase because of higher-than-expected effectiveness. Data on
adherence shows that the amount of drug used in IPERGAY was
about 50% of what would be used with full adherence to daily dosing.
An ongoing international study, HPTN067 (ADAPT),
randomises participants to three different regimens: daily PrEP; PreP twice a
week regardless of the chance of sex, with an extra post-exposure dose if sex occurs (time-driven);
or one dose of PrEP 24 hours before anticipated sex, followed by one
post-exposure dose two hours after sex (event-driven). This study was closed to
follow-up in December and results are expected soon.
Looking at various sexual patterns and comparing them with
the ADAPT and IPERGAY intermittent regimens, clearly if men had no sex one
week, money would be saved if PrEP was taken according to either of the event-driven
regimens, compared to the time-driven regimen. But if they had sex, the IPERGAY
regimen would end up with the highest pill usage because it requires four
pills. If there was one occasion of sex in the week, or two on consecutive
days, then the ADAPT event-driven regimen would be the most economic with only
two pills used; but if there were two occasions of sex separated by a day or
more, then the ADAPT time-driven regimen would be as economic as the
event-driven regimen.
These results are based on 100% prediction reliability, i.e.
that in all event-driven regimens, the participants do end up having sex.
However the researchers comment that due to the chance of ‘false negatives’ the
IPERGAY protocol may actually be the safest, for two reasons.If men end up
having sex more than twice a week, their PrEP coverage in IPERGAY would be at
least four doses a week, which is the
level that the iPrEx study predicts would be effective. Also, IPERGAY allows them to take Truvada
the day on which they anticipate sex, rather than the day before. They thus
recommend the ADAPT fixed-dose regimen, with a dose only omitted if there is no
chance of sex, for men who have sex no more than once a week on one day or two
consecutive days, but the IPERGAY regimen for men who have sex on more than two days a week or on
days that are not consecutive.
One major limitation of this study was that it only looked
at casual sex, even in the case of the 16% of men who had a steady partner. Men’s
ability to predict sex - or to postpone it if PrEP has not been taken – may be
greater in situations of sex with a regular partner, and more research is
needed on the predictability of sex within regular relationships.